Wird geladen...
Enzalutamide, an androgen receptor antagonist, enhances myeloid cell-mediated immune suppression and tumor progression
Androgen receptor (AR) antagonism increases overall survival in prostate cancer; however, treatment failure leads to tumor progression and patient mortality. The effect of AR modulation on AR(+) non-tumor cells that participate in the resistance to AR antagonism is poorly understood. Tumor-infiltrat...
Gespeichert in:
| Veröffentlicht in: | Cancer Immunol Res |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7484281/ https://ncbi.nlm.nih.gov/pubmed/32661092 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-19-0371 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|